Zevra Therapeutics Reports Inducement Grant to New Chief Financial Officer Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

Zevra Therapeutics (Nasdaq: ZVRA) granted an inducement equity award to new CFO Justin Renz effective March 18, 2026 under its 2023 Employment Inducement Award Plan.

The company approved a new-hire option for 300,000 shares with a 10-year term, exercise price of $9.55 (closing price on March 18, 2026), and four-year vesting subject to continued service. The award was approved under Nasdaq Rule 5635(c)(4).

News Market Reaction – ZVRA

+2.06%

+2.06% Session close to close

In the Mar 23 session, ZVRA gained 2.06%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement formalizes the equity component of Zevra’s new CFO hire, granting 300,000 stock op...

Analysis

This announcement formalizes the equity component of Zevra’s new CFO hire, granting 300,000 stock options at an exercise price of $9.55 over a 10-year term, vesting across four years. It follows a recent string of significant updates, including strong 2025 financial results and a $50 million asset sale. Investors may monitor future filings for additional executive grants, broader compensation trends, and how governance decisions intersect with Zevra’s rare disease commercial strategy.

Key Figures

Option grant size: 300,000 shares Exercise price: $9.55 per share Option term: 10 years +5 more

8 metrics

Option grant size 300,000 shares New hire stock option for CFO under 2023 Inducement Award Plan

Exercise price $9.55 per share Equal to ZVRA closing price on March 18, 2026

Option term 10 years Duration of CFO inducement stock option

Vesting period 4 years Option vests over four years, service-based

Grant date March 18, 2026 Date equity inducement award was granted

Nasdaq rule Rule 5635(c)(4) Governs equity inducement grants outside shareholder plans

Current share price $9.23 Pre-news price, slightly below $9.55 option exercise price

52-week range $6.19–$13.16 Current price 29.86% below 52-week high, 49.11% above low

Historical Context

5 past events · Latest: Mar 16 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Mar 16	Asset sale & debt	Positive	+1.6%	Sold SDX portfolio for $50M and highlighted debt-free balance sheet.
Mar 10	Genetic testing deal	Positive	+21.3%	Sponsored NPC genetic testing program with GeneDx to expand diagnosis access.
Mar 09	Q4/FY 2025 earnings	Positive	+21.3%	Reported strong Q4 growth, $106.5M FY revenue and $83.2M net income.
Mar 05	CFO appointment	Positive	-1.6%	Named Justin Renz CFO with extensive biopharma finance experience.
Mar 02	Earnings call date	Neutral	+1.8%	Announced timing and access details for Q4 and FY 2025 results call.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent history shows strong positive reactions to financial and strategic updates, with a divergence on the earlier CFO appointment headline.

Recent Company History

Over recent weeks, Zevra reported several notable developments. A $50 million SDX portfolio sale and debt repayment on Mar 16 saw a modest gain. A sponsored NPC genetic testing program with GeneDx and strong Q4/FY 2025 results around Mar 9–10 each coincided with 21.27% gains. The earlier appointment of Justin Renz as CFO on Mar 5 drew a slight negative move, contrasting with positive responses to financial news. Today’s inducement option grant follows that leadership transition and formalizes his equity package.

Key Terms

nasdaq rule 5635(c)(4), equity inducement award, exercise price

3 terms

nasdaq rule 5635(c)(4) regulatory

"approved by the Compensation Committee ... in accordance with Nasdaq Rule 5635(c)(4)"

NASDAQ Rule 5635(c)(4) is a listing standard that requires a company to obtain shareholder approval before issuing a substantial number of new shares or convertible securities in certain financing or insider-related transactions that would materially dilute existing holders. It matters to investors because the vote gives shareholders a check on deals that could significantly change ownership stakes or voting power—like a homeowners’ association approving a major renovation that affects the whole neighborhood’s value.

equity inducement award financial

"announced that the Company has granted ... an equity inducement award to Justin Renz"

An equity inducement award is a grant of company stock or stock-based rights given to a new employee as a hiring incentive, paid in addition to normal pay and benefit programs. It works like a signing bonus but in company shares, aligning the hire’s interests with shareholders while also increasing the number of outstanding shares; investors watch these awards for their impact on ownership dilution, executive motivation, and reported compensation costs.

exercise price financial

"an exercise price per share equal to $9.55, which was the closing price"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

BOSTON, March 20, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced that the Company has granted as of March 18, 2026 an equity inducement award to Justin Renz, the Company’s new Chief Financial Officer pursuant to the Company’s 2023 Employment Inducement Award Plan (as amended and/or restated, the “Inducement Award Plan”). The equity award was approved by the Compensation Committee of the Board of Directors in accordance with Nasdaq Rule 5635(c)(4) and made as a material inducement to Mr. Renz upon acceptance of employment with Zevra.

The Company granted Mr. Renz a new hire option to purchase 300,000 shares of Zevra’s common stock. The option has a 10-year term and an exercise price per share equal to $9.55, which was the closing price of Zevra’s common stock on March 18, 2026. The option vests over four years, subject to Mr. Renz’s continued service through the applicable vesting dates.

About Zevra Therapeutics, Inc.

Zevra Therapeutics, Inc. is a commercial-stage company with a late-stage pipeline committed to redefining what is possible in bringing life-changing therapies to people living with rare diseases. The Company is focused on broadening access through geographic expansion opportunities, progressing its pipeline toward key milestones, and delivering meaningful therapeutics. The commercialization of its lead product, marketed in the U.S. for Niemann-Pick disease type C (NPC), a rare, progressive neurodegenerative disease, provides a strong corporate foundation and validates its ability to advance therapies from development to market. Zevra's vision is realized through disciplined execution of its strategic plan and core values — patient centricity, integrity, accountability, innovation, and courage — which guide its efforts to deliver long-term value.

For more information, please visit www.zevra.com or follow us on X and LinkedIn.

Investor Contact

Nichol Ochsner 
+1 (732) 754-2545 
nochsner@zevra.com  

Media Contact

Julie Downs
+1 (508) 246-3230
jdowns@zevra.com

FAQ

What inducement award did Zevra (ZVRA) grant to its new CFO Justin Renz on March 18, 2026?

Zevra granted Justin Renz a new-hire option to purchase 300,000 shares of common stock. According to the company, the option has a 10-year term, $9.55 exercise price (closing price March 18, 2026) and vests over four years with continued service.

How does the exercise price of ZVRA's option for the new CFO compare to market price on March 18, 2026?

The option exercise price equals the market close on March 18, 2026 at $9.55 per share. According to the company, the exercise price was set equal to the closing price on that date per Nasdaq inducement rules.

What are the vesting and term details of the Zevra (ZVRA) CFO option awarded March 18, 2026?

The option vests over four years and carries a 10-year term from grant. According to the company, vesting is subject to Mr. Renz's continued service through applicable vesting dates.

Why was Zevra (ZVRA) required to approve the CFO equity award under Nasdaq Rule 5635(c)(4)?

Nasdaq Rule 5635(c)(4) permits equity inducements for newly hired executives with board approval. According to the company, the Compensation Committee approved the award as a material inducement upon Mr. Renz accepting employment.

Will the 300,000-share option awarded to Zevra (ZVRA) CFO cause immediate dilution to shareholders?

The option itself does not cause immediate dilution until exercised, which would issue shares then. According to the company, the award is an option grant that vests over time and requires exercise to create new shares.